# Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer

> **NCT00049166** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 48 (actual)

## Conditions studied

- Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity
- Stage II Squamous Cell Carcinoma of the Oropharynx
- Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
- Stage III Squamous Cell Carcinoma of the Oropharynx
- Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity
- Stage IV Squamous Cell Carcinoma of the Oropharynx

## Interventions

- **DRUG:** erlotinib hydrochloride
- **DRUG:** cisplatin
- **RADIATION:** intensity-modulated radiation therapy
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00049166
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2007-07
- **Final completion:** —
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2013-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00049166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00049166, "Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00049166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*